Journal article
Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases
DB Costa, AT Shaw, SHI Ou, BJ Solomon, GJ Riely, MJ Ahn, C Zhou, S Martin Shreeve, P Selaru, A Polli, P Schnell, KD Wilner, R Wiltshire, D Ross Camidge, L Crinò
Journal of Clinical Oncology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2015
Abstract
Purpose: Crizotinib is an oral kinase inhibitor approved for the treatment of ALK-rearranged non-small-cell lung cancer (NSCLC). The clinical benefits of crizotinib in patients with brain metastases have not been previously studied. Patients and Methods: Patients with advanced ALK-rearranged NSCLC enrolled onto clinical trial PROFILE 1005 or 1007 (randomly assigned to crizotinib) were included in this retrospective analysis. Patients with asymptomatic brain metastases (nontarget or target lesions) were allowed to enroll. Tumor assessments were evaluated every 6 weeks using RECIST (version 1.1). Results: At baseline, 31% of patients (275 of 888) had asymptomatic brain metastases; 109 had rece..
View full abstractGrants
Awarded by American Society of Clinical Oncology
Funding Acknowledgements
Supported by Pfizer and in part by Grants No. CA090578, CA058187, and CA164273 from the National Cancer Institute, by the American Society of Clinical Oncology Conquer Cancer Foundation, and by Grant No. RSG 11-186 from the American Cancer Society.